Allergy Therapeutics PLC Issue of equity in respect of exercise of options (5040L)
October 03 2016 - 5:28AM
UK Regulatory
TIDMAGY
RNS Number : 5040L
Allergy Therapeutics PLC
03 October 2016
3 October 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Issue of equity in respect of the exercise of options
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
the issue and allotment of 3,441,000 new ordinary shares of 0.1p
each in the capital of the Company ("Ordinary Shares") pursuant to
the exercise of 3,441,000 share options by certain employees. Of
this number of share options, an amount of the share options have
been exercised by persons discharging management responsibility
("PDMRs").
At the same time, the Company has received notice from certain
PDMRs that they have immediately sold Ordinary Shares in respect of
the share options exercised.
The exercise of share options and the sale of Ordinary Shares by
the respective PDMRs are detailed below:
Resulting
Ordinary percentage
Shares Resulting of voting
received Price beneficial rights
upon exercise Ordinary per Ordinary holding in the
of share Shares share of Ordinary Company
PDMR options sold sold Shares at Admission
----------------- --------------- --------- -------------- ------------- --------------
Sue Baker 160,000 160,000 19.0p 27,900 0.01%
----------------- --------------- --------- -------------- ------------- --------------
Alastair
Friend 80,000 80,000 19.5p - -
----------------- --------------- --------- -------------- ------------- --------------
Nunzio Di
Grazia 452,500 452,500 19.5p - -
----------------- --------------- --------- -------------- ------------- --------------
Bev Lees 160,000 160,000 19.5p - -
----------------- --------------- --------- -------------- ------------- --------------
Russell Pickett 160,000 160,000 19.5p - -
----------------- --------------- --------- -------------- ------------- --------------
Santiago
Puig 452,500 452,500 19.5p - -
----------------- --------------- --------- -------------- ------------- --------------
Murray Skinner 160,000 160,000 19.5p - -
----------------- --------------- --------- -------------- ------------- --------------
Bodo Steinert 452,500 226,250 19.5p 388,262 0.07%
----------------- --------------- --------- -------------- ------------- --------------
Application has been made to the London Stock Exchange for
admission to trading of the 3,441,000 new Ordinary Shares on AIM
("Admission") in respect of the exercise of the share options. It
is expected that Admission will take place and that dealings in the
new Ordinary Shares on AIM will commence at 8:00 a.m. on 6 October
2016, at which time the sale of Ordinary Shares will occur. The new
Ordinary Shares will, when issued, be credited as fully paid and
will rank pari passu in all respects with the existing Ordinary
Shares in the capital of the Company, including the right to
receive all dividends or other distributions made, paid or declared
in respect of such shares after the date of issue of the new
Ordinary Shares.
Allergy Therapeutics' enlarged issued ordinary share capital
immediately following Admission will be 593,364,020 Ordinary Shares
with voting rights attached. The Company has no Ordinary Shares in
Treasury; therefore, the total number of voting rights in Allergy
Therapeutics is 593,364,020. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in,
or a change to their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAEEDEAKKFFF
(END) Dow Jones Newswires
October 03, 2016 06:28 ET (10:28 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024